OncoMatch/Clinical Trials/NCT06482801
Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT
Is NCT06482801 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies ipilimumab+pembrolizumab or ipilimumab+durvalumab, idarubicin, bevacizumab for liver cancer.
Treatment: ipilimumab+pembrolizumab or ipilimumab+durvalumab, idarubicin, bevacizumab — This trial is designed to investigate the safety, response rates and survival outcomes of patients with hepatocellular carcinoma by infusion of CTLA4, PD1 and PDL1 antibodies combination with chemodrug or/and bevacizumab through intra-tumor (IT).
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: clinical trial agent or device
Patients participated in clinical trials of equipment or drugs (signed informed consent) within 4 weeks
Lab requirements
Blood counts
WBC ≥ 3.0×10E9/L; Hb ≥ 90g/L; PLT ≥ 50×10E9/L; INR < 2.3 or PT < 6 seconds above control; Impaired clotting test (platelet count < 60000/mm3, prothrombin activity < 50%) [excluded]
Kidney function
Cr ≤ 145.5 umul/L; Renal failure / insufficiency requiring hemo- or peritoneal dialysis [excluded]
Liver function
Child-Pugh class A or B/Child score > 7; Albumin > 28 g/L; Total bilirubin < 51 μmol/L
Child-Pugh class A or B/Child score > 7; WBC≥3.0×10E9/L; Hb≥90g/L； PLT ≥50×10E9/L；INR < 2.3 or PT < 6 seconds above control；Cr ≤ 145.5 umul/L；Albumin > 28 g/L；Total bilirubin < 51 μmol/L; Impaired clotting test (platelet count < 60000/mm3, prothrombin activity < 50%) [excluded]; Renal failure / insufficiency requiring hemo- or peritoneal dialysis [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify